Menu
MLA Diagnostics
A revolutionary prognostic test for early stage melanoma
Problem
Melanoma is the most deadly form of skin cancer. After diagnosis it is vital to know the risk of whether the disease is likely to spread. Prognostic information is important at this stage. Unfortunately current prognostic tools often classify patients as low risk but these patients still progress to metastatic disease and die without getting the treatment they needed.
Solution
MLA Diagnostics’ innovative product is an in vitro diagnostic (IVD) method that is able to determine melanoma patients with low or high metastatic risk.
Performed by the pathologist, this test provides more insight on a patients’ expected outcome and will enable a different course of treatment (more or less intensive).
News from MLA Diagnostics
MLA Diagnostics is awarded a LBDF POP subsidy by LIOF
The LBDF POP grant will support a Health Technology Assessment project in collaboration with Clinical Epidemiology & Medical Technology Assessment (KEMTA) and HI-NL. The project consisted
Egbert Smit October 30, 2019
MLA Diagnostics receives EIT Headstart funding
MLA Diagnostics has recently received EIT funding from the Headstart program. With this funding the company will boost development the company’s Quality and Regulatory strategy.
Egbert Smit October 14, 2019
MLA Diagnostics receives a place in the MSD LAB1891 programme
LAB1891 and UtrechtInc will partner up to support 3 early stage startups selected by MSD to help innovation in their focus area. The programme provided coaching, workshops and
Egbert Smit August 16, 2019
MIT Haalbaarheid subsidy received
The Mkb-innovatiestimulering Regio en Topsectoren (MIT) stimulates innovation in SMEs to align project with the top sectors. MLA Diagnostics received funding for a feasibility project
Egbert Smit June 6, 2019
Contact Us
Visit us in Maastricht
Where research and entrepreneurship come together